insights.uglyresearch.com
Battling antimicrobial resistance, visualizing data, and value in health. - INSIGHTS WEEKLY by Ugly Research
http://insights.uglyresearch.com/2016/09/dentists-antibiotics-epi-pen-bayesian.html
Laquo; Social determinants of health, nonfinancial performance metrics, and satisficers. Social program science, gut-bias decision test, and enough evidence already. ». Battling antimicrobial resistance, visualizing data, and value in health. Board of the Week : Dentists will slow down on antibiotics if you show them a chart of their prescribing numbers. Peer-reviewed: An Audit and Feedback Intervention for Reducing Antibiotic Prescribing in General Dental Practice. From the authors: "The feedback provid...
insights.uglyresearch.com
INSIGHTS WEEKLY by Ugly Research: healthcare & health tech
http://insights.uglyresearch.com/healthcare-evidence-based-medicine-healthit
35 posts categorized "healthcare and health tech". Social program science, gut-bias decision test, and enough evidence already. The driving force behind MDRC is a conviction that reliable evidence, well communicated, can make an important difference in social policy." -Gordon L. Berlin, President, MDRC. 1 Slice of the week. Can behavioral science improve the delivery of child support programs? Not to discount the excellent work by @CABS MDRC. A commitment to using best evidence to support decision making.
placebocontrol.com
Placebo Control: June 2013
http://www.placebocontrol.com/2013_06_01_archive.html
A review of key issues in pharmaceutical clinical trials. Friday, June 21, 2013. Preview of Enrollment Analytics: Moving Beyond the Funnel (Shameless DIA Self-Promotion, Part 2). Are we looking at our enrollment data in the right way? I will be chairing a session on Tuesday on this topic, joined by a couple of great presenters (Diana Chung from Gilead and Gretchen Goller from PRA). Here's a short preview of the session:. Hope to see you there. It should be a great discussion. June 25, 1:45PM - 3:15PM.
placebocontrol.com
Placebo Control: Waiver of Informed Consent - proposed changes in the 21st Century Cures Act
http://www.placebocontrol.com/2015/07/waiver-of-informed-consent-proposed.html
A review of key issues in pharmaceutical clinical trials. Tuesday, July 14, 2015. Waiver of Informed Consent - proposed changes in the 21st Century Cures Act. Adam Feuerstein points out - and expresses considerable alarm over - an overlooked clause in the 21. Waive informed consent requirement for clinical trials? Unbelievable but true if #Path2Cures. Becomes law. pic.twitter.com/dqmWPpxPdE. 8212; Adam Feuerstein (@adamfeuerstein) July 14, 2015. The act may, in fact, be helpful in those situations. Secti...
placebocontrol.com
Placebo Control: January 2013
http://www.placebocontrol.com/2013_01_01_archive.html
A review of key issues in pharmaceutical clinical trials. Friday, January 25, 2013. Less than Jaw-Dropping: Half of Sites Are Below Average. Last week, the Tufts Center for the Study of Drug Development unleashed the latest. In their occasional series of dire pronouncements about the state of pharmaceutical clinical trials. One particular factoid from the CSDD "study" caught my attention:. 57% of these racers won't medal! Many industry reporters uncritically recycled those numbers. Pharmalot. If you beli...
placebocontrol.com
Placebo Control: March 2014
http://www.placebocontrol.com/2014_03_01_archive.html
A review of key issues in pharmaceutical clinical trials. Tuesday, March 18, 2014. These Words Have (Temporarily) Relocated. Near the end of last year, I had the bright idea of starting a second blog,. To capture a lot of smaller items that I found interesting but wasn't going to work up into a full-blown, 1000 word post. First, my team at CAHG Trials. Launched a new blog,. FPI is dedicated to an open discussion of patient recruitment ideas, and I’m extremely proud of what we've published so far. My inau...
placebocontrol.com
Placebo Control: January 2014
http://www.placebocontrol.com/2014_01_01_archive.html
A review of key issues in pharmaceutical clinical trials. Sunday, January 12, 2014. Megafund versus Megalosaurus: Funding Drug Development. This new 10-minute TEDMED talk is getting quite a bit of attention:. If embedded video does not work, try the TED site itself. In it, Roger Stein claims to have created an approach to advancing drugs through clinical trials that will "fundamentally change the way research for cancer and lots of other things gets done". 9 billion estimated 2013 R&D spend. Many times m...
placebocontrol.com
Placebo Control: June 2014
http://www.placebocontrol.com/2014_06_01_archive.html
A review of key issues in pharmaceutical clinical trials. Tuesday, June 10, 2014. I have to admit to maybe being a little unsure about the " Dpharm: Disruptive Innovations to Advance Clinical Trials. A more cynical man than I might look at the high entry price, the posh venue, and the perhaps-somewhat-predictable list of long-time pharma insiders presenting and think: is this really the group that is going to change the status quo in clinical trials, or is this the group that created. Last year's 5/5 whi...
placebocontrol.com
Placebo Control: July 2015
http://www.placebocontrol.com/2015_07_01_archive.html
A review of key issues in pharmaceutical clinical trials. Tuesday, July 14, 2015. Waiver of Informed Consent - proposed changes in the 21st Century Cures Act. Adam Feuerstein points out - and expresses considerable alarm over - an overlooked clause in the 21. Waive informed consent requirement for clinical trials? Unbelievable but true if #Path2Cures. Becomes law. pic.twitter.com/dqmWPpxPdE. 8212; Adam Feuerstein (@adamfeuerstein) July 14, 2015. The act may, in fact, be helpful in those situations. Secti...
placebocontrol.com
Placebo Control: September 2013
http://www.placebocontrol.com/2013_09_01_archive.html
A review of key issues in pharmaceutical clinical trials. Wednesday, September 25, 2013. Brave New Biopharm Blogging. Although a few articles on this site are older, I really only began blogging in earnest about 15 months ago. However, I suppose that's long enough that I can count myself as at least somewhat established, and take a moment to welcome and encourage some interesting newcomers to the scene. The Big Pharma insider. Frank also gets my vote for most under-followed Twitter account. Clinical oper...
SOCIAL ENGAGEMENT